Ziaei S, Norrozi M, Faghihzadeh S, Jafarbegloo E
Department of Obstetrics and Gynecology, Faculty of Medical Science, Tarbiat Modarres University, Tehran, Iran.
BJOG. 2007 Jun;114(6):684-8. doi: 10.1111/j.1471-0528.2007.01325.x.
To study the effect of iron supplementation on pregnancy outcome in pregnant women with haemoglobin (Hb) > or = 13.2 g/dl.
A randomised, double-blind, placebo-controlled trial.
Routine health services.
Seven hundred and twenty-seven pregnant women with Hb > or = 13.2 g/dl in the early stage of the second trimester.
Each woman took one ferrous sulphate [DOSAGE ERROR CORRECTED] tablet (150 g tablet, containing 50 mg of elemental iron) [DOSAGE ERROR CORRECTED] daily in the case group (n = 370) or placebo in the control group (n = 357) throughout pregnancy.
Pregnancy outcome.
While there were no significant differences in demographic and obstetric characteristics between the two groups before any intervention, small-for-gestational-age birth rate and the number of women with hypertension disorder increased significantly in the case group in comparison with the control group (57 [15.7%] versus 36 [10.3%], P = 0.035, 10 [2.7%] versus 3 [8%], P = 0.05, respectively).
Our finding proves that routine iron supplementation in nonanaemic women is not rational and may be harmful.
研究铁补充剂对血红蛋白（Hb）≥13.2g/dl的孕妇妊娠结局的影响。
一项随机、双盲、安慰剂对照试验。
常规卫生服务机构。
727名孕中期早期血红蛋白≥13.2g/dl的孕妇。
病例组（n = 370）的每位孕妇在整个孕期每天服用一片硫酸亚铁片（剂量已校正，150mg片剂，含50mg元素铁），对照组（n = 357）服用安慰剂。
妊娠结局。
在任何干预之前，两组的人口统计学和产科特征无显著差异，但与对照组相比，病例组的小于胎龄儿出生率和高血压疾病女性人数显著增加（分别为57例[15.7%]对36例[10.3%]，P = 0.035；10例[2.7%]对3例[0.8%]，P = 0.05）。
我们的研究结果证明，对非贫血女性常规补充铁剂不合理且可能有害。
